| Protein Tyrosine Phosphatase 1B Inhibitors: A Molecular Level Legitimate Approach for the Management of Diabetes Mellitus. | |
| | |
MedLine Citation:
|
PMID: 20814956 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
Diabetes mellitus is a systemic disease responsible for morbidity in the western world and is gradually becoming prevalent in developing countries too. The prevalence of diabetes is rapidly increasing in industrialized countries and type 2 diabetes accounts for 90% of the disease. Insulin resistance is a major pathophysiological factor in the development of type 2 diabetes, occurring mainly in muscle, adipose tissues, and liver leading to reduced glucose uptake and utilization and increased glucose production. The prevalence and rising incidence of diabetes emphasized the need to explore new molecular targets and strategies to develop novel antihyperglycemic agents. Protein Tyrosine Phosphatase 1B (PTP 1B) has recently emerged as a promising molecular level legitimate therapeutic target in the effective management of type 2 diabetes. PTP 1B, a cytosolic nonreceptor PTPase, has been implicated as a negative regulator of insulin signal transduction. Therefore, PTP 1B inhibitors would increase insulin sensitivity by blocking the PTP 1B-mediated negative insulin signaling pathway and might be an attractive target for type 2 diabetes mellitus and obesity. With X-ray crystallography and NMR-based fragment screening, the binding interactions of several classes of inhibitors have been elucidated, which could help the design of future PTP 1B inhibitors. The drug discovery research in PTP 1B is a challenging area to work with and many pharmaceutical organizations and academic research laboratories are focusing their research toward the development of potential PTP 1B inhibitors which would prove to be a milestone for the management of diabetes. © 2010 Wiley Periodicals, Inc. Med Res Rev, 32, No. 3, 459-517, 2012. |
| | |
Authors:
|
Suresh Thareja; Saurabh Aggarwal; T R Bhardwaj; Manoj Kumar |
Related Documents
:
|
20811656 - D-chiro-inositol glycans in insulin signaling and insulin resistance. 1331176 - Regulation of insulin receptor substrate-1 in liver and muscle of animal models of insu... 18436806 - Trib3 r84 variant is associated with impaired insulin-mediated nitric oxide production ... 19163256 - A wavelet denoising approach for signal action isolation in the ear canal. 12592416 - Circulating biomarkers of oxidative stress in complicated pregnancies. 22094836 - Impact of treatment with oral calcitriol on glucose indices in type 2 diabetes mellitus... |
Publication Detail:
|
Type: Journal Article Date: 2010-09-02 |
Journal Detail:
|
Title: Medicinal research reviews Volume: 32 ISSN: 1098-1128 ISO Abbreviation: Med Res Rev Publication Date: 2012 May |
Date Detail:
|
Created Date: 2012-04-27 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8103150 Medline TA: Med Res Rev Country: United States |
Other Details:
|
Languages: eng Pagination: 459-517 Citation Subset: IM |
Copyright Information:
|
© 2010 Wiley Periodicals, Inc. |
Affiliation:
|
University Institute of Pharmaceutical Sciences, Panjab University, 160 014, Chandigarh, India. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: BMI and fracture risk in older men: the osteoporotic fractures in men study (MrOS).
Next Document: Peptide-mediated targeted drug delivery.